KR20240108412A - 안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물 - Google Patents

안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물 Download PDF

Info

Publication number
KR20240108412A
KR20240108412A KR1020247016730A KR20247016730A KR20240108412A KR 20240108412 A KR20240108412 A KR 20240108412A KR 1020247016730 A KR1020247016730 A KR 1020247016730A KR 20247016730 A KR20247016730 A KR 20247016730A KR 20240108412 A KR20240108412 A KR 20240108412A
Authority
KR
South Korea
Prior art keywords
formula
amino
peptidomimetic
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016730A
Other languages
English (en)
Korean (ko)
Inventor
데니스 키프
마르틴 레드몬
브라이언 호치키스
앤서니 아브루스카토
Original Assignee
스텔스 바이오테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/045908 external-priority patent/WO2023069255A1/en
Application filed by 스텔스 바이오테라퓨틱스 인코포레이티드 filed Critical 스텔스 바이오테라퓨틱스 인코포레이티드
Publication of KR20240108412A publication Critical patent/KR20240108412A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247016730A 2021-10-20 2022-10-19 안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물 Pending KR20240108412A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163257738P 2021-10-20 2021-10-20
US63/257,738 2021-10-20
US202263331412P 2022-04-15 2022-04-15
US63/331,412 2022-04-15
PCT/US2022/045908 WO2023069255A1 (en) 2021-10-20 2022-10-06 Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
USPCT/US2022/045908 2022-10-06
PCT/US2022/047172 WO2023069549A1 (en) 2021-10-20 2022-10-19 Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions

Publications (1)

Publication Number Publication Date
KR20240108412A true KR20240108412A (ko) 2024-07-09

Family

ID=84329344

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016730A Pending KR20240108412A (ko) 2021-10-20 2022-10-19 안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물

Country Status (8)

Country Link
US (1) US20230405080A1 (https=)
EP (1) EP4419123A1 (https=)
JP (1) JP2024539150A (https=)
KR (1) KR20240108412A (https=)
AU (1) AU2022370358A1 (https=)
CA (1) CA3234071A1 (https=)
IL (1) IL312199A (https=)
WO (1) WO2023069549A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719404A2 (en) * 2023-05-25 2026-04-08 Stealth BioTherapeutics Inc. Methods for addressing injection site reactions associated with the administration of bevemipretide
CN117982412B (zh) * 2024-02-04 2024-09-17 济川(上海)医学科技有限公司 一种醋克利定眼用组合物及其药物制剂和用途
US20260048096A1 (en) * 2024-08-19 2026-02-19 Stealth Biotherapeutics Inc. Methods and compositions for preserving the retinal outer nuclear layer (onl), photoreceptors, and retinal thickness

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2521515T3 (es) * 2008-04-04 2014-11-12 Mimetogen Pharmaceuticals Inc. Compuestos cíclicos peptidomiméticos con giro beta para tratar el ojo seco
AU2015264908B2 (en) * 2008-05-09 2017-06-29 Pari Pharma Gmbh Nebuliser for Ventilation Machines and a Ventilation Machine Comprising such a Nebuliser
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
CN104244964A (zh) * 2012-02-22 2014-12-24 康肽德生物医药技术有限公司 用于预防或治疗眼科病状的方法和组合物
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
CN115919996A (zh) * 2015-05-01 2023-04-07 雅利斯塔制药公司 用于治疗眼科疾病的脂联素拟肽
ES2942631T3 (es) * 2017-12-15 2023-06-05 Stealth Biotherapeutics Inc Péptidos dirigidos a mitocondrias
CN112165954A (zh) * 2018-03-23 2021-01-01 阿奇生物外科有限公司 用于治疗眼病的sap和拟肽
AU2020316449B2 (en) * 2019-07-24 2026-02-05 Stealth Biotherapeutics Inc. The peptidomimetic compound (R)-2-amino-N-((S)-L-(((S)-5-amino-L-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5-guanidinopentanamide in the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
JP2024539150A (ja) 2024-10-28
AU2022370358A1 (en) 2024-05-02
IL312199A (en) 2024-06-01
WO2023069549A1 (en) 2023-04-27
US20230405080A1 (en) 2023-12-21
EP4419123A1 (en) 2024-08-28
CA3234071A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
KR20240108412A (ko) 안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물
US20240024408A1 (en) Methods and compositions for preventing or treating leber's hereditary optic neuropathy
US20240350577A1 (en) Methods and compositions for preventing or treating dominant optic atrophy
JP7638265B2 (ja) 神経変性疾患の治療におけるペプチド模倣化合物（ｒ）－２－アミノ－ｎ－（（ｓ）－ｌ－（（（ｓ）－５－アミノ－ｌ－（３－ベンジル－１，２，４－オキサジアゾール－５－イル）ペンチル）アミノ）－３－（４－ヒドロキシ－２，６－ジメチルフェニル）－ｉ－オキソプロパン－２－イル）－５－グアニジノペンタンアミド
EP3756665B1 (en) Interval therapy for the treatment of eye diseases
US20200055849A1 (en) Integrin antagonists
WO2023069255A1 (en) Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
CN118434434A (zh) 用于治疗、预防、抑制、改善眼科病状或延缓其发作的方法和包括肽模拟物的组合物
JP4566130B2 (ja) 角膜知覚回復剤
US20250090504A1 (en) Small molecule peptidomimetic for the treatment of tauopathies
US20250025526A1 (en) Combination therapy for the treatment of friedreich's ataxia
WO2026043737A1 (en) Methods and compositions for preserving the retinal outer nuclear layer (onl), photoreceptors, and retinal thickness
CN119497612A (zh) 用于治疗亨廷顿病和htt蛋白病的组合物和方法
HK40051528A (en) Integrin antagonists

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000